On October 9, Twist Bioscience Corp rose 5.27% in regular trading, trading at $160.06 per share, with turnover of $37.65 million. The move follows Jefferies initiating coverage with a Hold rating and a $150 price target, which, while offering limited upside, eased near-term valuation divergence and released some selling pressure.
Background shows the stock had fallen 5.63% the prior session amid broad biotech weakness and heightened valuation concerns in the synthetic DNA space. Jefferies' price target provided an anchor for recent volatility, helping stabilize sentiment despite the target being near current trading levels.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)